Navigation Links
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
Date:10/2/2007

ISIS 325568 is an Antisense Drug Targeting Glucagon Receptor for Treatment

of Type 2 Diabetes

CARLSBAD, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has earned $5 million from Ortho-McNeil, Inc. (OMI), a Johnson & Johnson company, for achieving the first development milestone of initializing the Phase 1 clinical trial of ISIS 325568.

The collaboration between Isis and OMI, announced on September 13, 2007, includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131, both of which represent novel approaches for the treatment of metabolic disease. ISIS 325568 was designed to selectively inhibit the production of glucagon receptor and has demonstrated improved glucose control in animal models of Type 2 diabetes.

"We are pleased to have achieved this milestone so early in our collaboration with Ortho-McNeil, Inc.," said Jeffrey Jonas, M.D., Executive Vice President, Isis Pharmaceuticals. "OMI will be providing all funding for this study, while Isis will be managing the study through to completion before handing all additional development responsibilities over to our partner."

ABOUT GLUCAGON RECEPTOR (GCGR), TARGET OF ISIS 325568

Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In Type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and help control Type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to im
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
4. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
5. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, announced today that the first patient ... clinical trial of AGT-181 in patients with attenuated ... AGT-181 is an investigational enzyme replacement therapy (ERT) ... severe form of MPS I, Hurler syndrome, is ...
(Date:9/2/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at the Rodman & Renshaw 17th Annual Global ... at 9:35 a.m. ET on Thursday, September 10, 2015. ... via live audio webcast which can be accessed by visiting ... http://www.aethlonmedical.com . The webcast will be archived for thirty ...
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... , President and Chief Executive Officer, will present ... Global Investment Conference, sponsored by H.C. Wainwright ... September 8-10, 2015 at the St. Regis Hotel ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... On September 9, 2015, over 27,000 people from ... largest single-company convention to date for the state of Utah. , “We are thrilled ... event,” states David Stirling, doTERRA CEO. “One of the most exciting elements of our ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... the likelihood of it dropping. , Tablets like the iPad and Samsung Galaxy Tab ...
(Date:9/2/2015)... ... 2015 , ... The payroll conference theme this year is ... covering legislative updates, including unemployment, global payroll best practices, and the latest trends ... Software, the American Payroll Association, Barnett Associates, and the IRS, will keep payroll ...
(Date:9/2/2015)... ... September 02, 2015 , ... Pentec Health, Inc., a national leader ... for an impressive sixth consecutive year. Less than 5 % of this year’s 5000 ... the “health” sector. Pentec’s 3-year revenue growth rate of 65% sustained its most ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... If the man who mowed down 32 persons at Virginia Tech ... you call the man who has devised a computer game ... rampage, players control an image of Korean-born gunman Cho Seung-hui. Screams ... the other characters. ,21-year-old Ryan Lambourn, an Australian, ...
... reward the federal government with their vote at the next ... the same time he concedes that two bad post-budget polls ... ,"I'm confident that come Election Day, people will reward ... Abbott was quoted. He said he was confident voters had ...
... extended time are the most common but contentious accommodation ... and/or AD/HD taking college entrance and licensing exams. According ... Practice, students given extra time respond to exams similarly ... ,According to my research, there is no real evidence ...
... Director-General of the World Health Organization, has called upon all member ... that would handicap the organization in the fight contain bird blu. ... . I would fail you," said he said in a speech ... countries, Chan said that "you are tying my hands, you're muffling ...
... past, the newborns umbilical cord was not clamped right ... naturally. This practice , known as late clamping, was ... immediately after the infant is expelled. However, this new ... studies on the importance of when clamping should be ...
... on animals, conducted by the National Toxicology Program (NTP), ... as hexavalent chromium (chromium 6) causes cancer when ... ,Hexavalent chromium compounds are often used in electroplating, leather ... some drinking water sources. ,The two-year study ...
Cached Medicine News:Health News:Australian Devises Online Game Based on Virginia Tech Shootout 2Health News:Tony Abbott Confident Of Australias Vote For Performance Not Promise 2Health News:WHO Director Urges Nations to Share Bird Flu Virus Strains 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 3
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: